Published in Cytokine on May 18, 2013
Cytokines in immune-mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications. Clin Exp Immunol (2014) 0.90
Association between Prediagnostic Allergy-Related Serum Cytokines and Glioma. PLoS One (2015) 0.80
Kinetic Differences and Synergistic Antiviral Effects Between Type I and Type III Interferon Signaling Indicate Pathway Independence. J Interferon Cytokine Res (2015) 0.79
Investigating the Role of TNF-α and IFN-γ Activation on the Dynamics of iNOS Gene Expression in LPS Stimulated Macrophages. PLoS One (2016) 0.79
Prothymosin α variants isolated from CD8+ T cells and cervicovaginal fluid suppress HIV-1 replication through type I interferon induction. J Infect Dis (2014) 0.78
Constitutive IFNα/β signaling maintains expression of signaling intermediaries for efficient cytokine responses. JAKSTAT (2016) 0.75
Tumor Necrosis Factor Inhibits Spread of Hepatitis C Virus Among Liver Cells, Independent from Interferons. Gastroenterology (2017) 0.75
Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol (2008) 8.85
Tumour necrosis factors alpha and beta inhibit virus replication and synergize with interferons. Nature (1986) 4.81
Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier. Nat Immunol (2004) 2.51
Induction of the synthesis of tumor necrosis factor receptors by interferon-gamma. J Immunol (1986) 2.00
Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer Res (2005) 1.91
Interferon-gamma enhances expression of cellular receptors for tumor necrosis factor. J Immunol (1986) 1.91
Late phase inhibition of murine cytomegalovirus replication by synergistic action of interferon-gamma and tumour necrosis factor. J Gen Virol (1994) 1.89
Human gamma interferon and tumor necrosis factor exert a synergistic blockade on the replication of herpes simplex virus. J Virol (1989) 1.71
Alpha/Beta interferon and gamma interferon synergize to inhibit the replication of herpes simplex virus type 1. J Virol (2002) 1.65
Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Res (2007) 1.50
Immune responses to myxoma virus. Viral Immunol (2002) 1.50
RIG-I mediates the co-induction of tumor necrosis factor and type I interferon elicited by myxoma virus in primary human macrophages. PLoS Pathog (2008) 1.49
Anti-human cytomegalovirus activity of cytokines produced by CD4+ T-cell clones specifically activated by IE1 peptides in vitro. J Virol (1996) 1.40
The addition of tumor necrosis factor plus beta interferon induces a novel synergistic antiviral state against poxviruses in primary human fibroblasts. J Virol (2008) 1.32
Antiviral activity of tumour necrosis factor. Synergism with interferons and induction of oligo-2',5'-adenylate synthetase. J Gen Virol (1988) 1.26
Evolutionary history and attenuation of myxoma virus on two continents. PLoS Pathog (2012) 1.22
Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo. Mol Ther (2007) 1.16
Human cancer cells have specifically lost the ability to induce the synergistic state caused by tumor necrosis factor plus interferon-beta. Cytokine (2009) 1.14
IFN-α in the treatment of melanoma. J Immunol (2012) 1.12
Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors. Clin Cancer Res (2008) 1.08
Tumor necrosis factor and interferon: cytokines in harmony. Curr Opin Microbiol (2008) 1.08
Myxoma virus is oncolytic for human pancreatic adenocarcinoma cells. Ann Surg Oncol (2008) 1.06
Emerging role of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) as a key regulator of inflammatory responses. Clin Exp Pharmacol Physiol (2009) 1.04
Beta interferon and gamma interferon synergize to block viral DNA and virion synthesis in herpes simplex virus-infected cells. J Gen Virol (2005) 1.04
The immunoregulatory properties of oncolytic myxoma virus and their implications in therapeutics. Microbes Infect (2010) 1.03
Antimicrobial and immunoregulatory effects mediated by human lung cells: role of IFN-gamma-induced tryptophan degradation. FEMS Immunol Med Microbiol (2008) 1.00
Role of the protein kinase PKR in the inhibition of varicella-zoster virus replication by beta interferon and gamma interferon. J Gen Virol (2005) 1.00
Myxoma virus sensitizes cancer cells to gemcitabine and is an effective oncolytic virotherapeutic in models of disseminated pancreatic cancer. Mol Ther (2012) 1.00
Tumour necrosis factor-alpha, interferon-gamma and interferon-beta exert antiviral activity in nervous tissue cells. J Gen Virol (1991) 0.97
Independent and cooperative antiviral actions of beta interferon and gamma interferon against herpes simplex virus replication in primary human fibroblasts. J Virol (2007) 0.96
Myxoma virus combined with rapamycin treatment enhances adoptive T cell therapy for murine melanoma brain tumors. Cancer Immunol Immunother (2011) 0.95
Interferon-alpha in the treatment of multiple myeloma. Curr Drug Targets (2011) 0.90
Synergistic inhibition of Epstein-Barr virus: transformation of B lymphocytes by alpha and gamma interferon and by 3'-azido-3'-deoxythymidine. J Infect Dis (1989) 0.89
Host-specificity of myxoma virus: Pathogenesis of South American and North American strains of myxoma virus in two North American lagomorph species. Vet Microbiol (2009) 0.88
Interferon-α for patients with chronic hepatitis delta: a systematic review of randomized clinical trials. Antivir Ther (2012) 0.88
Interferon-gamma-induced assembly block in the replication cycle of adenovirus 2: augmentation by tumour necrosis factor-alpha. Virology (1992) 0.88
The synergistic interaction of interferon types I and II leads to marked reduction in severe acute respiratory syndrome-associated coronavirus replication and increase in the expression of mRNAs for interferon-induced proteins. Intervirology (2006) 0.82
Influence of input multiplicity of infection on the antiviral activity of interferon. J Gen Virol (1980) 0.81
The in vitro antiviral activity of tumor necrosis factor (TNF) in WISH cells is mediated by IFN-beta induction. Antiviral Res (1989) 0.80
The synergistic effect of IFN-alpha and IFN-gamma against HSV-2 replication in Vero cells is not interfered by the plant antiviral 1-cinnamoyl-3, 11-dihydroxymeliacarpin. Virol J (2006) 0.78
Poxviruses and immune evasion. Annu Rev Immunol (2001) 4.80
Anti-immunology: evasion of the host immune system by bacterial and viral pathogens. Cell (2006) 3.83
A poxvirus-encoded pyrin domain protein interacts with ASC-1 to inhibit host inflammatory and apoptotic responses to infection. Immunity (2005) 3.43
Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier. Nat Immunol (2004) 2.51
Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc Natl Acad Sci U S A (2006) 1.96
Role of the serine-threonine kinase PAK-1 in myxoma virus replication. J Virol (2003) 1.69
Modulation of NF-κB signalling by microbial pathogens. Nat Rev Microbiol (2011) 1.64
Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer. Expert Opin Biol Ther (2007) 1.63
Myxoma virus in the European rabbit: interactions between the virus and its susceptible host. Vet Res (2007) 1.55
Smallpox: anything to declare? Nat Rev Immunol (2002) 1.53
Poxvirus immunomodulatory strategies: current perspectives. J Virol (2003) 1.52
The PHD/LAP-domain protein M153R of myxomavirus is a ubiquitin ligase that induces the rapid internalization and lysosomal destruction of CD4. J Virol (2003) 1.52
Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Res (2007) 1.50
Immune responses to myxoma virus. Viral Immunol (2002) 1.50
RIG-I mediates the co-induction of tumor necrosis factor and type I interferon elicited by myxoma virus in primary human macrophages. PLoS Pathog (2008) 1.49
When good vaccines go wild: Feral Orthopoxvirus in developing countries and beyond. J Infect Dev Ctries (2008) 1.40
The myxoma poxvirus protein, M11L, prevents apoptosis by direct interaction with the mitochondrial permeability transition pore. J Exp Med (2002) 1.39
Modulation of tumor necrosis factor by microbial pathogens. PLoS Pathog (2006) 1.34
Neutrophils recruited to sites of infection protect from virus challenge by releasing neutrophil extracellular traps. Cell Host Microbe (2013) 1.33
The addition of tumor necrosis factor plus beta interferon induces a novel synergistic antiviral state against poxviruses in primary human fibroblasts. J Virol (2008) 1.32
Co-regulation of NF-kappaB and inflammasome-mediated inflammatory responses by myxoma virus pyrin domain-containing protein M013. PLoS Pathog (2009) 1.32
Myxoma virus: propagation, purification, quantification, and storage. Curr Protoc Microbiol (2010) 1.29
Myxoma virus M11L prevents apoptosis through constitutive interaction with Bak. J Virol (2004) 1.27
Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells. J Virol (2006) 1.25
Poxvirus host range genes. Adv Virus Res (2008) 1.23
Myxoma virus M141R expresses a viral CD200 (vOX-2) that is responsible for down-regulation of macrophage and T-cell activation in vivo. J Virol (2005) 1.20
NFkB inhibitors: strategies from poxviruses. Cell Cycle (2009) 1.18
Poxviruses and apoptosis: a time to die. Curr Opin Microbiol (2002) 1.17
Technical knockout: understanding poxvirus pathogenesis by selectively deleting viral immunomodulatory genes. Cell Microbiol (2004) 1.16
Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo. Mol Ther (2007) 1.16
Human cancer cells have specifically lost the ability to induce the synergistic state caused by tumor necrosis factor plus interferon-beta. Cytokine (2009) 1.14
M062 is a host range factor essential for myxoma virus pathogenesis and functions as an antagonist of host SAMD9 in human cells. J Virol (2011) 1.13
Viral chemokine-binding proteins. J Leukoc Biol (2002) 1.13
Adipose-derived stem cells as therapeutic delivery vehicles of an oncolytic virus for glioblastoma. Mol Ther (2009) 1.13
Secreted immunomodulatory viral proteins as novel biotherapeutics. J Immunol (2004) 1.13
Proteomic screening of variola virus reveals a unique NF-kappaB inhibitor that is highly conserved among pathogenic orthopoxviruses. Proc Natl Acad Sci U S A (2009) 1.11
Structure of M11L: A myxoma virus structural homolog of the apoptosis inhibitor, Bcl-2. Protein Sci (2007) 1.11
The role of cell signaling in poxvirus tropism: the case of the M-T5 host range protein of myxoma virus. Biochim Biophys Acta (2007) 1.09
Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors. Clin Cancer Res (2008) 1.08
Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin. Cancer Res (2010) 1.08
Immunopathogenesis of poxvirus infections: forecasting the impending storm. Immunol Cell Biol (2007) 1.08
Tumor necrosis factor and interferon: cytokines in harmony. Curr Opin Microbiol (2008) 1.08
Analysis of vaccinia virus-host protein-protein interactions: validations of yeast two-hybrid screenings. J Proteome Res (2009) 1.07
Identification of host range mutants of myxoma virus with altered oncolytic potential in human glioma cells. J Neurovirol (2007) 1.06
Myxoma virus M11L blocks apoptosis through inhibition of conformational activation of Bax at the mitochondria. J Virol (2006) 1.06
Myxoma virus M128L is expressed as a cell surface CD47-like virulence factor that contributes to the downregulation of macrophage activation in vivo. Virology (2005) 1.06
Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus. Cytokine Growth Factor Rev (2010) 1.06
Myxoma virus is oncolytic for human pancreatic adenocarcinoma cells. Ann Surg Oncol (2008) 1.06
Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus. Biol Blood Marrow Transplant (2012) 1.06
M-T5, the ankyrin repeat, host range protein of myxoma virus, activates Akt and can be functionally replaced by cellular PIKE-A. J Virol (2006) 1.05
Complete genomic sequence and comparative analysis of the tumorigenic poxvirus Yaba monkey tumor virus. J Virol (2003) 1.05
Myxoma virus expressing interleukin-15 fails to cause lethal myxomatosis in European rabbits. J Virol (2009) 1.04
Optimization of codon usage of poxvirus genes allows for improved transient expression in mammalian cells. Virus Genes (2006) 1.03
The immunoregulatory properties of oncolytic myxoma virus and their implications in therapeutics. Microbes Infect (2010) 1.03
Myxoma virus M063R is a host range gene essential for virus replication in rabbit cells. Virology (2006) 1.03
The 'supervirus'? Lessons from IL-4-expressing poxviruses. Trends Immunol (2005) 1.02
A secreted high-affinity inhibitor of human TNF from Tanapox virus. Proc Natl Acad Sci U S A (2003) 1.02
Cowpox virus expresses a novel ankyrin repeat NF-kappaB inhibitor that controls inflammatory cell influx into virus-infected tissues and is critical for virus pathogenesis. J Virol (2009) 1.00
Myxoma virus sensitizes cancer cells to gemcitabine and is an effective oncolytic virotherapeutic in models of disseminated pancreatic cancer. Mol Ther (2012) 1.00
Interplay between poxviruses and the cellular ubiquitin/ubiquitin-like pathways. FEBS Lett (2009) 0.99
Oncolytic virotherapy for hematological malignancies. Adv Virol (2011) 0.99
Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes? Curr Opin Mol Ther (2008) 0.98
Poxvirus proteomics and virus-host protein interactions. Microbiol Mol Biol Rev (2009) 0.98
Myxoma virus protein M029 is a dual function immunomodulator that inhibits PKR and also conscripts RHA/DHX9 to promote expanded host tropism and viral replication. PLoS Pathog (2013) 0.97
Myxoma virus infection of primary human fibroblasts varies with cellular age and is regulated by host interferon responses. Virology (2005) 0.97
The myxoma virus m-t5 ankyrin repeat host range protein is a novel adaptor that coordinately links the cellular signaling pathways mediated by Akt and Skp1 in virus-infected cells. J Virol (2009) 0.95
Myxoma virus combined with rapamycin treatment enhances adoptive T cell therapy for murine melanoma brain tumors. Cancer Immunol Immunother (2011) 0.95
Oncolytic myxoma virus: the path to clinic. Vaccine (2013) 0.95
The serpin saga; development of a new class of virus derived anti-inflammatory protein immunotherapeutics. Adv Exp Med Biol (2009) 0.94
M135R is a novel cell surface virulence factor of myxoma virus. J Virol (2006) 0.94
Acute myeloid leukemia targeting by myxoma virus in vivo depends on cell binding but not permissiveness to infection in vitro. Leuk Res (2012) 0.94
Inhibition of macrophage activation by the myxoma virus M141 protein (vCD200). J Virol (2009) 0.94
Myxoma and vaccinia viruses exploit different mechanisms to enter and infect human cancer cells. Virology (2010) 0.93
Viral chemokine-binding proteins inhibit inflammatory responses and aortic allograft transplant vasculopathy in rat models. Transplantation (2004) 0.92
Targeting gallbladder cancer: oncolytic virotherapy with myxoma virus is enhanced by rapamycin in vitro and further improved by hyaluronan in vivo. Mol Cancer (2014) 0.92
Identification of myxomaviral serpin reactive site loop sequences that regulate innate immune responses. J Biol Chem (2006) 0.90
Bugs and drugs: oncolytic virotherapy in combination with chemotherapy. Curr Pharm Biotechnol (2012) 0.90
Myxoma and vaccinia viruses bind differentially to human leukocytes. J Virol (2013) 0.90
A randomized controlled, phase 2 trial of the viral serpin Serp-1 in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Circ Cardiovasc Interv (2010) 0.90
The current status and future directions of myxoma virus, a master in immune evasion. Vet Res (2011) 0.90
Myxoma virus induces type I interferon production in murine plasmacytoid dendritic cells via a TLR9/MyD88-, IRF5/IRF7-, and IFNAR-dependent pathway. J Virol (2011) 0.89
Poxvirus tumor necrosis factor receptor (TNFR)-like T2 proteins contain a conserved preligand assembly domain that inhibits cellular TNFR1-induced cell death. J Virol (2006) 0.89
Virotherapy using myxoma virus prevents lethal graft-versus-host disease following xeno-transplantation with primary human hematopoietic stem cells. PLoS One (2012) 0.89
Analysis of an orf virus chemokine-binding protein: Shifting ligand specificities among a family of poxvirus viroceptors. Proc Natl Acad Sci U S A (2003) 0.89
The poxvirus C7L host range factor superfamily. Curr Opin Virol (2012) 0.88
Strategies that modulate inflammasomes: insights from host-pathogen interactions. Semin Immunopathol (2007) 0.88
Induction of alpha/beta interferon by myxoma virus is selectively abrogated when primary mouse embryo fibroblasts become immortalized. J Virol (2009) 0.88
Positive evolutionary selection on the RIG-I-like receptor genes in mammals. PLoS One (2013) 0.88
Oncolytic virotherapy for pancreatic cancer. Expert Rev Mol Med (2011) 0.88
Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin. Neuro Oncol (2013) 0.87
Myxoma virus M064 is a novel member of the poxvirus C7L superfamily of host range factors that controls the kinetics of myxomatosis in European rabbits. J Virol (2012) 0.87
Inhibition of chemokine-glycosaminoglycan interactions in donor tissue reduces mouse allograft vasculopathy and transplant rejection. PLoS One (2010) 0.86
Comparative genetic analysis of genomic DNA sequences of two human isolates of Tanapox virus. Virus Res (2007) 0.86
Serp-1, a viral anti-inflammatory serpin, regulates cellular serine proteinase and serpin responses to vascular injury. J Biol Chem (2003) 0.86
Poxvirus cancer therapy. Recent Pat Antiinfect Drug Discov (2006) 0.86
Evolution and divergence of the mammalian SAMD9/SAMD9L gene family. BMC Evol Biol (2013) 0.86
Myxoma virus-mediated oncolysis of ascites-derived human ovarian cancer cells and spheroids is impacted by differential AKT activity. Gynecol Oncol (2012) 0.86
Pharmacological manipulation of the akt signaling pathway regulates myxoma virus replication and tropism in human cancer cells. J Virol (2010) 0.86
Myxoma virus infection promotes NK lysis of malignant gliomas in vitro and in vivo. PLoS One (2013) 0.85